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n-3 Fatty acids have clinical benefits. The primary aim of the present study was the assessment of infection in patients who underwent major high-
risk elective gastrointestinal surgery receiving postoperatively fish oil (FO)-supplemented parenteral nutrition (PN), compared with those receiving
a standard olive oil (OO) emulsion. The secondary aims were the assessment of anti-inflammatory response and evaluation of tolerance and safety
of these emulsions. A prospective, randomised, double-blind study was performed in patients requiring at least 5 d of PN. An isoenergetic and
isoproteic formula was administered: group A received OO alone, while group B received OO that was partially replaced with FO (16·6 %,
w/w). End points were outcome measures (mortality, sepsis, infection, hospitalisation days and PN duration), inflammatory response (C-reactive
protein (CRP), prealbumin and leucocytes) and safety (TAG and glucose metabolism, and liver and kidney function). Statistical analysis was done
using Student’s t test and Fisher’s exact test (P,0·05). Twenty-seven patients were evaluated, with thirteen patients receiving FO. In this group, a
significantly lower incidence of infections was found (23·1 v. 78·6 %, P¼0·007). CRP, prealbumin and leucocytes were not significantly different
between the groups. There were no differences in safety parameters. We conclude that high-risk surgical patients receiving FO-supplemented PN
for 5 d present a lower incidence of infection. Emulsions were safe and well tolerated.
Total parenteral nutrition: Fish oil: Olive oil: Gastrointestinal surgery: Infection
Critically ill patients and those who have undergone surgery
are at a high risk of developing infectious complications
due to, among other reasons, a compromised immune status
caused by the inflammatory process they experience(1).
Lipids in parenteral nutrition (PN) provide a major source of
energy, essential fatty acids and liposoluble vitamins, as well
as cell membrane components and eicosanoid and cytokine
precursors, and they are attributed pharmacological functions
that may intervene in the clinical course of the disease(2).
The first soya oil-based lipid emulsions were associated
with an altered response in inflammatory processes, which
was suggested to contribute to greater susceptibility to
infection and a poorer clinical outcome(3). The concern over
this potentially harmful consequence has led to the develop-
ment of alternative lipid emulsions. Olive oil (OO)-based
emulsions provide an immunoneutral option(3) with clinical
advantages(3 – 5) and proven tolerance and safety(4). Fish oil
(FO) emulsions are considered immunomodulators due to
their capacity to modify both the synthesis of bioactive
metabolites such as eicosanoids, released with hydrolysis of
cell membrane phospholipids, and cytokine production(2).
Despite these theoretical advances, there are few clinical
trials examining the definitive impact of administering a
single pharmaconutrient on the patients’ clinical outcome(6,7),
and none of them directly compares OO and FO.
The primary aim of the present study was to assess the
relationship between infection and FO-supplemented PN
compared to a standard OO emulsion following a high-risk
elective major surgery. The secondary aims included assess-
ment of the patients’ anti-inflammatory response and evalu-
ation of the safety of, and tolerance to, these emulsions.
Methods
Setting and study design
A prospective, randomised, double-blind study was performed
in a 900-bed, third-level teaching hospital in Barcelona
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(Spain) in patients undergoing elective gastrointestinal tract
major surgery. The sample size was calculated according to
one hypothesis based on qualitative variables (50 % reduction
in the incidence of infections) and another hypothesis based on
quantitative variables (25 % difference in C-reactive protein
values) by considering an a error of 5 % and statistical
power of 80 %. The final population required was therefore
proposed to comprise at least twelve patients per group.
Patients were randomly allocated to two groups by consecu-
tively assigning them a number from a randomisation table.
Patients who were assigned an even number were placed in
the control group, and those who were assigned an odd
number were placed in the intervention group.
Patients and inclusion criteria
The study included adult patients who had undergone an
elective gastrointestinal major surgery and required at least
5 d of PN. Patients were excluded for metabolic disease,
chronic kidney or liver failure, severe haemorrhagic disorder,
unstable diabetes, shock, sepsis, congestive heart disease,
acute myocardial infarction, stroke, coma of unknown cause,
HIV, dyslipoproteinaemia, neutropaenia, contraindications
for lipid administration, current immunosuppressive or anti-
neoplastic treatment, obesity or low weight, PN during the
15 d before hospitalisation, surgical intervention within 30 d
before hospitalisation and expected fatal outcome.
Study period
From October 2002 to June 2003, twenty-nine patients were
randomised. The study began once the patients had undergone
surgery and the need for PN had been established. PN was
started the day after the surgery. Patients were followed up
from the day of the surgery until the day of discharge from
the hospital. Seven different teams participated in the surgical
interventions. Patients were hospitalised in the postoperative
recovery unit, intensive care unit, and/or general surgery and
gastrointestinal wards.
Nutritional intervention
PN was administered as ‘all-in-one’ mixtures that were
prepared daily in the Pharmacy Service, and was delivered
in masked containers. Neither the patient nor the expert
assessor knew which lipid emulsion was being used. All PN
formulas were administered using an infusion pump over
24 h. Oral or enteral ingestion was not allowed.
Group A (control) received PN with OO lipid emulsion, and
group B (intervention) received PN where a part of the OO
emulsion had been substituted by FO in a proportion of
16·6 % (w/w), providing the same final amount of lipids.
Both groups received the same supply of nitrogen
(0·2–0·3 g/kg per d), energies (83·7–125.5 kJ/kg per d or
20–30 kcal/kg per d) and lipids (0·7–1 g/kg per d). All
patients received the same solution of amino acids and glucose
(Aminomixw; Fresenius-Kabi, Barcelona, Spain), vitamins
(Cernevitw; Baxter, Madrid, Spain) and trace elements
(Addamelw; Fresenius-Kabi). Commercial preparations were
used for the administration of FO (Omegavenw; Fresenius-
AB, Bad Homburg, Germany) and OO (Clinoleicw; Baxter).
OO emulsions contain 20 % soya oil. They are rich in
long-chain MUFA, mainly n-9, and contain 20 % PUFA
with an 8:1 ratio of n-6:n-3. FO-based lipids, rich in n-3
PUFA, present a 1:8 ratio of n-6:n-3, and contain high amounts
of n-3 family fatty acids (EPA and DHA) and vitamin E.
Blood extraction
Analytical parameters were determined on the day of
the surgery, before starting PN, on day 6 and after 5 d of
PN administration. Blood was drawn at approximately
07.00 hours. Determinations were performed at the Clinical
Laboratory of our hospital, which has been certified according
to the UNE-EN-ISO 15189:2003 standard.
Clinical follow-up
Follow-up included daily monitoring of vital signs, allergic
reactions, signs of infection, cardiac alterations, gastrointesti-
nal tract dysfunction, lung processes, renal or hepatic dys-
function, haematological signs and behavioural disorders.
Concomitant medication, fluid replacement therapy and
blood administration were recorded.
Clinical outcome
The incidence of death, sepsis and non-septic infection was
recorded, as well as both the number of hospitalisation days
and the days PN treatment was received. Non-septic infection
was established by clinical evidence and at least one positive
culture from samples of lung (sputum or bronchoalveolar
lavage), urine, blood, abdomen (peritoneal fluid or abdominal
abscess) or surgical wound. Sepsis was defined on the basis of
at least one positive culture plus two or more of the following
conditions: leucocytes . 12 £ 109 cells/l or ,4 £ 109 cells/l,
body temperature , 358C or .388C, heart rate . 90/min
and PaCO2 , 32 mmHg.
Inflammatory response
The evolution of the inflammatory response was determined
by C-reactive protein, prealbumin and leucocyte count after
5 d of PN.
Safety of the infusion
TAG and glucose metabolism, hepatic function (g-glutamyl-
transferase, alkaline phosphatase and alanine aminotransferase)
and renal function (urea and creatinine) were specifically
determined on day 6 following surgery to assess tolerance to
the infused emulsion.
Statistical analysis
Student’s t test and Fisher’s exact test were performed.
Significance was set at a P value ,0·05. SPSS 13.0 was
used for the calculations (SPSS, Inc., Cary, NC, USA).
The present study was conducted according to the guide-
lines stated in the Declaration of Helsinki, and all procedures
involving human patients were approved by the ‘Comitè Ètic

















d’Investigació Clı́nica de l’Hospital Universitari de Bellvitge’.
Written informed consent was obtained from all patients.
Results
Clinical characteristics
Initially, twenty-nine patients were randomised, but two
patients were excluded. Among the twenty-seven patients
assessed (median age 65 years; range 32–84), 66·6 % (n 18)
were men.
Twelve patients had large gastric adenocarcinoma (IIIA or
IIIB). All the surgeries were open total gastrectomy with
large lymphadenectomy; splenectomy was performed in six
cases and pancreatectomy in four cases. In seven cases, a par-
tial colectomy and partial small intestine resection were per-
formed. Blood transfusion was necessary in ten cases. PN
was indicated because the option of performing a successful
jejunostomy for feeding was not considered an option.
Ten patients had pancreatic ductal adenocarcinoma (IIB or
III). They underwent open duodenopancreatectomy, and all
received blood transfusion, and in all but one, surgery took
6 h or more. After this kind of intervention, PN is the support
diet regimen most frequently used in our hospital.
Three patients had oesophageal adenocarcinoma (IIB or
III). They underwent open oesophagectomy (radical resection
and reconstruction), and gastrectomy was also performed in
two cases. They received PN because their nutritional status
before the intervention was not considered adequate.
Two patients underwent colectomy, both with open surgery.
One patient underwent a total colectomy with partial resection
of small intestine because of a massive polyposis. The other
patient underwent a combination of colectomy, hysterectomy,
pancreatectomy and partial gastrectomy because of a gynaeco-
logical cancer with metastasis. Both patients received blood
transfusion and finished with one or more stomata. The
length of these interventions was over 6 h. They received
PN because of the extensive resections.
Fourteen patients received standard PN (group A), and thir-
teen patients received PN supplemented with FO (group B).
The baseline characteristics of both groups are presented in
Table 1. Use of concomitant medication and blood-related
products showed no significant differences (data not shown).
PN administration was carried out with no side effects in
any case, and there were no reported problems in this
regard. The nutrients administered are presented in Table 2.
Outcomes
Mortality, sepsis, infectious complications, hospital stay and
PN duration are presented in Table 2. The only statistically
significant difference was found in infectious complications:
eleven in group A (three respiratory, three abdominal, four
urinary and one surgical wound) and three in group B (one
abdominal, one surgical wound and one bloodstream infec-
tion) (P¼0·007).
Inflammatory response and safety of the infusions
No significant differences were found between the groups
(Table 2).
Discussion
A significantly lower incidence of non-septic infection was
observed in the FO-supplemented group.
FO acts as an immunomodulator(8 – 14) with protective
properties in the hyperinflammatory state of postoperative
patients(13). The low content of n-6 and high-a-tocopherol(15)
may contribute to an improvement in the oxidative state by
minimising lipid peroxidation(13). It must be emphasised
that this outcome may be attributed to FO, but the influence
of any particular component of this emulsion has not been
studied in the present study.
Table 1. Baseline patient characteristics
(Mean values and standard deviations; n and percentages)
OO OO þ FO
Patients (n 27) Mean SD % Mean SD % P
Age (years) 63·71 14·8 63·61 16·24 0·87*
Gender (n)
Men 11 78·5 7 53·8 0·21†
Women 3 21·4 6 46·2
BMI (kg/m2) 23·45 2·95 23·21 4·92 0·79*
Albumin (g/l) 27·84 7·23 28·55 5·53 0·54*
C-reactive protein (mg/l) 209·80 106 172·80 48·90 0·33*
Surgery (min) 307 117 275 107 0·21*
Normal renal function (n) 13 92·8 11 84·6 0·56†
Normal hepatic function (n) 10 71·4 10 73·9 0·78†
Surgery (n)
Oesophagectomy 1 2 0·23†
Gastrectomy 6 6 0·80†
Duodenopancreatectomy 6 4 0·44†
Colectomy 1 1 0·87†
OO, olive oil; FO, fish oil.
* Student’s t test.
† Fisher’s exact test.

















Results of related studies are in agreement with the fact that
the infection rate is lower in groups that receive FO, but the
differences found have not been shown to be statistically
significant(11,16). Indeed, the overall incidence of non-septic
infection in the present study is high, which could be attribu-
ted to the fact that the patients who were selected were
seriously ill, and had undergone quite complicated major sur-
gery; nevertheless, no significant difference was observed for
sepsis between the groups.
Differences regarding mortality were NS, which was con-
sistent with other studies(2,6,17,18). The high rate of mortality
observed in the present study could be attributed to the facts
that all the diseases were malignant in a high stage and
were treated through open surgery and in long interventions,
and that the albumin values before the intervention were low.
Clearly, there are two main limitations to the present
study: the small sample size and the lack of more inflamma-
tory and immunological markers. However, it should be
noted that the main focus of the study was the patients’
clinical outcome.
This is the first study that has compared the addition of FO
to an emulsion based on OO that has proven metabolic effi-
cacy and safety(19) and, in some studies, immunoneutral prop-
erties(20). It has been hypothesised that FO emulsions may
have an associated immune suppression which could reduce
the host resistance to infection(5). The present results provide
statistical support to the idea that the protective activity of
these lipids and the high amounts of vitamin E predominate
over an immunosuppressive effect with possible enhanced
susceptibility to infection. The maximum dose of FO is
established at 0·2 g/kg per d(1,7), although the proper balance
between n-3 and n-6 remains uncertain. In the present
study, the ratio was 1:1·6, with a content of 0·13–0·16 g of
FO/kg per d.
In conclusion, this is the first PN study that attempted to
define the impact of FO supplementation v. an OO-based
emulsion. The strength of the study in a limited number of
high-risk surgical patients during 5 d of PN was not sufficient
to assess the overall impact of OO v. FO supplementation.
Nonetheless, the FO-supplemented regimen demonstrated a
clear and statistically significant reduction in non-septic infec-
tion. Further studies in larger patient populations with more
extensive investigation of specific inflammatory markers are
needed to reassess these findings.
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Table 2. Parenteral intake, inflammatory response, emulsion safety and outcomes
(Mean values and standard deviations; n and percentages; medians and interquartile ranges (IQR))
OO (n 14) OO þ FO (n 13)
Mean SD Mean SD P *
Nutritional facts
Nitrogen (g/kg per d) 0·22 0·02 0·23 0·03 0·88
Glucose (g/kg per d) 3·15 0·38 3·42 0·40 0·82
Lipid (g/kg per d) 0·88 0·10 0·88 0·08 0·88
Volume (ml/d) 2124 234 2201 255 0·73
Non-protein energy (kJ/kg per d) 56·5 6·7 59·2 8·5 0·69
Total energy (kJ/kg per d) 93·1 9·5 99·9 10·8 0·71
Lipid (% non-protein energy) 39·40 2·79 38·31 2·78 0·78
Glucose (% non-protein energy) 56·67 2·75 57·69 2·78 0·79
Analytical parameters
C-reactive protein (mg/l) 188·3 94·3 142·3 69·3 0·16
Prealbumin (mg/l) 83·0 53·0 105·0 37·0 0·22
Leucocytes (£109 cells/l) 13·68 9·2 9·8 3·9 0·17
TAG (mmol/l) 1·77 0·82 1·81 0·49 0·89
Glucose (mmol/l) 9·28 3·43 9·27 4·79 0·99
GGT (mKat/l) 3·81 3·14 3·94 2·81 0·91
ALP (mKat/l) 2·48 0·66 2·69 1·46 0·65
ALT (mKat/l) 1·00 0·79 0·94 0·53 0·79
Urea (mmol/l) 9·32 5·00 8·23 2·00 0·46
Creatinine (mmol/l) 80·7 30·10 81·62 21·30 0·92
Outcomes n % n % P†
Mortality 2 14·3 1 7·7 0·529
Sepsis 5 35·7 1 7·7 0·098
Infection 11 78·6 3 23·1 0·007
Median IQR Median IQR P *
Hospital stay (d) 15 12 16 17 0·544
Duration of PN (d) 8 4·5 7 3·75 0·442
OO, olive oil; FO, fish oil; GGT, g-glutamyltransferase; ALP, alkaline phosphatase; ALT, alanine aminotransferase;
PN, parenteral nutrition.
* Student’s t test.
† Fisher’s exact test.
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1. Heller AR, Fischer S, Rössel T, et al. (2002) Impact of n-3 fatty
acid supplemented parenteral nutrition on haemostasis patterns
alter major abdominal surgery. Br J Nutr 87, Suppl. 1,
S95–S101.
2. Tsekos E, Reuter C, Stehle P, et al. (2004) Perioperative admin-
istration of parenteral fish oil supplements in a routine clinical
setting improves patient outcome alter major abdominal surgery.
Clin Nutr 23, 325–330.
3. Cury-Boaventura MF, Gorjao R, Martins de Lima T, et al.
(2008) Effect of olive oil-based emulsion on human lymphocyte
and neutrophil death. JPEN 32, 81–87.
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